Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2UME is the leading cause of moderate and severe vision